Bisdichloroacetyldiamines

Alternative Name: BDADs

Description: Bisdichloroacetyldiamines (BDADs, e.g. WIN 18,446) were shown to inhibit testicular retinoic acid biosynthesis and complete arrest of spermatogenesis.

Product Details

User: Female, Male

Hormonal: No

Delivery Method: Oral

Duration Type: Long-acting

Regimen:
  • daily

Active Pharmaceutical Ingredient (API):
  • Bis-dichloroacetyldiamine

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Focused Scientific, University of Washington

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Began discovery in: 2008

Active Development: No

Status Details:
  • Known to cause unpleasant disulfirim reactions when administered with alcohol due to inhibition of ALDH2 (involved in alcohol metabolism in liver), so further development was abandoned.
  • In females, WIN 18,446 treatment significantly reduced fecundity, but the compound’s disruption of fetal development makes its appeal as a contraceptive limited.

Additional Information

References:
  • Paik J, et al. (2018). Can inhibition of retinoic acid biosynthesis function as a non-hormonal female contraceptive? Contraception, 98(2), 141-143.

  • Beyler, A., et al. (1961). The selective testicular effects of certain bis-(dichloroacetyl) diamines. Endocrinology, 69(4), 819-833. 

Footnotes:
  • See also ALDH1A2 Inhibitors.

Vertical Tabs

Print